Title:
ANTI-TUMOR AGENT
Document Type and Number:
WIPO Patent Application WO/2006/088193
Kind Code:
A1
Abstract:
A therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor, the therapeutic agent comprising, as the active ingredient, a benzoyl compound represented by the general formula (I) or a prodrug or pharmacologically acceptable salt thereof: (I) wherein n is an integer of 1 to 5; R1 represents a substituted or unsubstituted lower alkoxy, a substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R3 and R5 independently represent a hydrogen atom, a substituted or unsubstituted lower alkyl or the like; R4 represents a hydrogen atom, a hydroxy or a halogen; and R6 represents a hydrogen atom, a halogen, a substituted or unsubstituted lower alkyl or the like.
Inventors:
KANDA YUTAKA
SOGA SHIRO
NAKASHIMA TAKAYUKI
NARA SHINJI
NAKAGAWA HIROSHI
SHIOTSU YUKIMASA
SOGA SHIRO
NAKASHIMA TAKAYUKI
NARA SHINJI
NAKAGAWA HIROSHI
SHIOTSU YUKIMASA
Application Number:
PCT/JP2006/302996
Publication Date:
August 24, 2006
Filing Date:
February 21, 2006
Export Citation:
Assignee:
KYOWA HAKKO KOGYO KK (JP)
KANDA YUTAKA
SOGA SHIRO
NAKASHIMA TAKAYUKI
NARA SHINJI
NAKAGAWA HIROSHI
SHIOTSU YUKIMASA
KANDA YUTAKA
SOGA SHIRO
NAKASHIMA TAKAYUKI
NARA SHINJI
NAKAGAWA HIROSHI
SHIOTSU YUKIMASA
International Classes:
A61K31/12; A61K31/165; A61K31/216; A61K31/343; A61K31/36; A61K31/381; A61K31/40; A61K31/4015; A61K31/4406; A61K31/445; A61K31/4535; A61K31/472; A61K31/495; A61K31/496; A61K31/506; A61K31/5375; A61K31/5377; A61P35/00; A61P35/02; C07D207/09; C07D207/12; C07D207/27; C07D211/22; C07D211/42; C07D211/52; C07D211/54; C07D211/60; C07D211/62; C07D213/40; C07D217/06; C07D239/42; C07D241/08; C07D295/08; C07D295/10; C07D295/12; C07D307/14; C07D317/54; C07D333/22; C07D409/10
Domestic Patent References:
| WO2005000778A1 | 2005-01-06 | |||
| WO2003055860A1 | 2003-07-10 |
Other References:
LEN N.: "Hsp90 inhibitors as novel cancer chemotherapeutic agents", TRENDS IN MOLECULAR MEDICINE, vol. 8, no. 4 (SUPPL.), 2002, pages S55 - S61, XP002246588
SOGA S. ET AL.: "KF25706, a novel oxime derivative of radicinol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules", CANCER RESEARCH, vol. 59, no. 12, 1999, pages 2931 - 2938, XP002287485
GEORGAKIS G. ET AL.: "The geldanamycin analogue heat shock protein 90 (HSP90) inhibitor 17-AAG in lymphomas: Molecular mechanisms of 17-AAG-induced cell death in Hodgkin disease and non-Hodgkin lymphoma cell lines", BLOOD, vol. 104, no. 11, PART 1, 2004, pages 899A, XP003000906
CAMPOS L. ET AL.: "Hsp90 Inhibitors induce apoptosis in human leukemia cells", BLOOD, vol. 104, no. 11, PART 1, 2004, pages 30A, XP003000907
See also references of EP 1852112A4
L. NECKERS, TRENDS IN MOLECULAR MEDICINE, vol. 8, no. 4, 2002
SOGA S. ET AL.: "KF25706, a novel oxime derivative of radicinol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules", CANCER RESEARCH, vol. 59, no. 12, 1999, pages 2931 - 2938, XP002287485
GEORGAKIS G. ET AL.: "The geldanamycin analogue heat shock protein 90 (HSP90) inhibitor 17-AAG in lymphomas: Molecular mechanisms of 17-AAG-induced cell death in Hodgkin disease and non-Hodgkin lymphoma cell lines", BLOOD, vol. 104, no. 11, PART 1, 2004, pages 899A, XP003000906
CAMPOS L. ET AL.: "Hsp90 Inhibitors induce apoptosis in human leukemia cells", BLOOD, vol. 104, no. 11, PART 1, 2004, pages 30A, XP003000907
See also references of EP 1852112A4
L. NECKERS, TRENDS IN MOLECULAR MEDICINE, vol. 8, no. 4, 2002
Download PDF:
Previous Patent: CARRIER FOR ANALYTICAL USE AND DETERMINATION METHOD USING THE SAME
Next Patent: UNDERWATER TRAINING AND REHABILITATION IMPLEMENT
Next Patent: UNDERWATER TRAINING AND REHABILITATION IMPLEMENT